<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03038438</url>
  </required_header>
  <id_info>
    <org_study_id>APV-ABRE</org_study_id>
    <nct_id>NCT03038438</nct_id>
  </id_info>
  <brief_title>ABRE Clinical Study of the Abre Venous Self-expanding Stent System</brief_title>
  <official_title>A Multi-center, Non-randomized Study to Evaluate the Safety and Effectiveness of the Abre Venous Self-expanding Stent System in Patients With Symptomatic Iliofemoral Venous Outflow Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and effectiveness of the Abre venous self-expanding stent system for&#xD;
      treatment of symptomatic iliofemoral venous outflow obstruction in patients with venous&#xD;
      occlusive disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Actual">January 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Primary Patency</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from occlusion of the stented segment; freedom from restenosis &gt;=50%; and Freedom from clinically-driven target lesion revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Composite Major Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>The components of the Major Adverse Events include:&#xD;
All-cause death occurring post-procedure, clinically-significant pulmonary embolism, major bleeding complication, stent thrombosis, and stent migration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Successful delivery and deployment of the stent and removal of the delivery system during the index procedure. Stent based outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Success Obtained at Index Procedure</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Venographic evidence of &lt;50% residual stenosis of the stented segment of the target lesion after post-dilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index Procedure Success</measure>
    <time_frame>30 days</time_frame>
    <description>Lesion success without procedure-related MAEs prior to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Primary Patency at 24 Months</measure>
    <time_frame>24 Months</time_frame>
    <description>Freedom from occlusion of the stented segment; freedom from restenosis &gt;=50%; and Freedom from clinically-driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Primary Patency at 36 Months</measure>
    <time_frame>36 Months</time_frame>
    <description>Freedom from occlusion of the stented segment; freedom from restenosis &gt;=50%; and Freedom from clinically-driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Primary Assisted Patency at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Primary assisted patency is defined as uninterrupted patency of the stented segment of the target lesion with a secondary intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Primary Assisted Patency at 24 Months</measure>
    <time_frame>24 Months</time_frame>
    <description>Primary assisted patency is defined as uninterrupted patency of the stented segment of the target lesion with a secondary intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Primary Assisted Patency at 36 Months</measure>
    <time_frame>36 Months</time_frame>
    <description>Primary assisted patency is defined as uninterrupted patency of the stented segment of the target lesion with a secondary intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Secondary Patency at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary patency is defined as patency of the stented segment of the target lesion after subsequent intervention for an occlusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Secondary Patency at 36 Months</measure>
    <time_frame>36 Months</time_frame>
    <description>Secondary patency is defined as patency of the stented segment of the target lesion after subsequent intervention for an occlusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Secondary Patency at 24 Months</measure>
    <time_frame>24 Months</time_frame>
    <description>Secondary patency is defined as patency of the stented segment of the target lesion after subsequent intervention for an occlusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization Through 30 Days, 6-, 12 Months</measure>
    <time_frame>30 days, 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization Through 24 Months</measure>
    <time_frame>24 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization Through 36 Months</measure>
    <time_frame>36 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events Through 30 Days, 6-, 12 Months</measure>
    <time_frame>30 days, 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events Through 24 Months</measure>
    <time_frame>24 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events Through 36 Months</measure>
    <time_frame>36 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed Stent Migration at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed Stent Migration at 24 Months</measure>
    <time_frame>24 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed Stent Migration at 36 Months</measure>
    <time_frame>36 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Fracture at 30 Days, 12 Months</measure>
    <time_frame>30 days (30 subjects) and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Fracture at 24 Months</measure>
    <time_frame>24 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Fracture at 36 Months</measure>
    <time_frame>36 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms QOL/Sym Score at 6-, 12 Months</measure>
    <time_frame>Baseline to 6 and 12 months</time_frame>
    <description>Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms (VEINES QOL/Sym). Higher scores correlate to better quality of life on a scale of 1-100. Change in VEINES QOL/Sym scores were calculated as the Baseline score minus the Follow-up score (6 or 12 months). A positive change is associated with improved outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms QOL/Sym Score at 24 Months</measure>
    <time_frame>24 Month</time_frame>
    <description>Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms (VEINES QOL/Sym). Higher scores correlate to better quality of life on a scale of 1-100. Change in VEINES QOL/Sym scores were calculated as the Baseline score minus the Follow-up score (24 months). A positive change is associated with improved outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms QOL/Sym Score at 36 Months</measure>
    <time_frame>36 Month</time_frame>
    <description>Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms (VEINES QOL/Sym). Higher scores correlate to better quality of life on a scale of 1-100. Change in VEINES QOL/Sym scores were calculated as the Baseline score minus the Follow-up score (36 months). A positive change is associated with improved outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Villalta Score at 6-, 12 Months Compared to Baseline</measure>
    <time_frame>Baseline to 6 and 12 months</time_frame>
    <description>Villalta scores categorize the severity of post-thrombotic syndrome (PTS). Higher score indicates increasing severity of PTS. A score of greater or equal to 5 indicates PTS. PTS severity: total score of 5 to 9, mild PTS; score of 10 to 14, moderate PTS; and score of greater or equal to 15 or venous ulcer present, severe PTS. Change in Villalta scores were calculated as the Baseline score minus the Follow-up score (6 or 12 months). A negative change is associated with improved outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Villalta Score at 24 Months Compared to Baseline</measure>
    <time_frame>24 Month</time_frame>
    <description>Villalta scores categorize the severity of post-thrombotic syndrome (PTS). Higher score indicates increasing severity of PTS. A score of greater or equal to 5 indicates PTS. PTS severity: total score of 5 to 9, mild PTS; score of 10 to 14, moderate PTS; and score of greater or equal to 15 or venous ulcer present, severe PTS. Change in Villalta scores were calculated as the Baseline score minus the Follow-up score (24 months). A negative change is associated with improved outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Villalta Score at 36 Months Compared to Baseline</measure>
    <time_frame>36 Month</time_frame>
    <description>Villalta scores categorize the severity of post-thrombotic syndrome (PTS). Higher score indicates increasing severity of PTS. A score of greater or equal to 5 indicates PTS. PTS severity: total score of 5 to 9, mild PTS; score of 10 to 14, moderate PTS; and score of greater or equal to 15 or venous ulcer present, severe PTS. Change in Villalta scores were calculated as the Baseline score minus the Follow-up score (36 months). A negative change is associated with improved outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQol-5 Dimension (EQ-5D) Score at 6-, 12 Months Compared to Baseline</measure>
    <time_frame>Baseline to 6 and 12 Months</time_frame>
    <description>Higher score indicates a better quality of life. The questionnaire contains five dimensions where scores rank from 1 (best) to 5 (worst) plus a visual analog scale (VAS) (0 = worst health; 100 = best health). A positive change is associated with improved outcome. Change in EQ-5D scores were calculated as the Baseline score minus the Follow-up score (6 or 12 months) for both the index and VAS scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQol-5 Dimension (EQ-5D) Score at 24 Months Compared to Baseline</measure>
    <time_frame>24 Month</time_frame>
    <description>Higher score indicates a better quality of life. The questionnaire contains five dimensions where scores rank from 1 (best) to 5 (worst) plus a visual analog scale (VAS) (0 = worst health; 100 = best health). A positive change is associated with improved outcome. Change in EQ-5D scores were calculated as the Baseline score minus the Follow-up score (24 months) for both the index and VAS scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQol-5 Dimension (EQ-5D) Score at 36 Months Compared to Baseline</measure>
    <time_frame>36 Month</time_frame>
    <description>Higher score indicates a better quality of life. The questionnaire contains five dimensions where scores rank from 1 (best) to 5 (worst) plus a visual analog scale (VAS) (0 = worst health; 100 = best health). A positive change is associated with improved outcome. Change in EQ-5D scores were calculated as the Baseline score minus the Follow-up score (36 months) for both the index and VAS scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Venous Clinical Severity Score (VCSS) at 6-, and 12 Months Compared to Baseline</measure>
    <time_frame>Baseline to 6 and 12 months</time_frame>
    <description>VCSS scores range from 0=no disease to 30=severe disease. Change in VCSS score was calculated as the Baseline score minus the Follow-up score (6 or 12 months). A negative change is associated with improved outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Venous Clinical Severity Score (VCSS) at 24 Months Compared to Baseline</measure>
    <time_frame>24 Month</time_frame>
    <description>VCSS scores range from 0=no disease to 30=severe disease. Change in VCSS score was calculated as the Baseline score minus the Follow-up score (24 months). A negative change is associated with improved outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Venous Clinical Severity Score (VCSS) at 36 Months Compared to Baseline</measure>
    <time_frame>36 Month</time_frame>
    <description>VCSS scores range from 0=no disease to 30=severe disease. Change in VCSS score was calculated as the Baseline score minus the Follow-up score (36 months). A negative change is associated with improved outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding Complication at 30 Days, 6-, 12 Months</measure>
    <time_frame>30 days, 6 months, and 12 months</time_frame>
    <description>A blood loss leading to transfusion of whole blood or red cells provided hemoglobin drop of 3 g/dL (1.86 mmol/L) or more is related to bleeding occurring during the index procedure through 12 months post-index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding Complication at 24 Months</measure>
    <time_frame>24 Month</time_frame>
    <description>A blood loss leading to transfusion of whole blood or red cells provided hemoglobin drop of 3 g/dL (1.86 mmol/L) or more is related to bleeding occurring during the index procedure through 24 months post-index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding Complication at 36 Months</measure>
    <time_frame>36 Month</time_frame>
    <description>A blood loss leading to transfusion of whole blood or red cells provided hemoglobin drop of 3 g/dL (1.86 mmol/L) or more is related to bleeding occurring during the index procedure through 36 months post-index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Re-hospitalization Through 12 Months</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Number of subjects that were re-hospitalized due to their target lesion within 180 days from the Index Procedure and number of subjects that were re-hospitalized due to their target lesion from 181 to 360 days from the Index Procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Re-hospitalization Through 24 Months</measure>
    <time_frame>24 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Re-hospitalization Through 36 Months</measure>
    <time_frame>36 Month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Iliofemoral Venous Obstruction</condition>
  <arm_group>
    <arm_group_label>Abre</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abre Venous Self-expanding Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abre venous self-expanding stent system</intervention_name>
    <description>venous stent</description>
    <arm_group_label>Abre</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is ≥ 18 and ≤ 80 years of age;&#xD;
&#xD;
          2. Patient has at least one of the following clinical manifestations (i.e. symptoms&#xD;
             and/or signs) of venous disease in lower extremity:&#xD;
&#xD;
               -  CEAP score ≥ 3&#xD;
&#xD;
               -  Venous Clinical Severity Score pain score (VCSS) ≥2&#xD;
&#xD;
               -  Suspected deep vein thrombosis (DVT);&#xD;
&#xD;
          3. Patient is willing and capable of complying with specified follow-up evaluations at&#xD;
             the specified times;&#xD;
&#xD;
          4. Patient has been informed of the nature of the study, agrees to its provisions and has&#xD;
             provided written informed consent, approved by the appropriate Ethics Board.&#xD;
&#xD;
          5. Patient has diagnosis of non-malignant venous obstruction within the common iliac,&#xD;
             external iliac, and/or common femoral vein. The proximal point of the obstruction may&#xD;
             extend to the iliac venous confluence of the inferior vena cava and the distal point&#xD;
             may be at or above the deep femoral vein. Diagnosis must be made based on objective&#xD;
             imaging by using venography and/or intravascular ultrasound (IVUS);&#xD;
&#xD;
          6. Patient has an obstructive lesion defined as:&#xD;
&#xD;
               -  Occluded, or&#xD;
&#xD;
               -  ≥50% in diameter reduction on venography or IVUS, or&#xD;
&#xD;
               -  ≥50% area reduction on IVUS&#xD;
&#xD;
          7. Acute DVT patients should be treated with the Abre stent within 14 days after onset of&#xD;
             symptoms. Patients with acute DVT must first undergo successful treatment of acute&#xD;
             thrombus by catheter based techniques; successful treatment is defined as 30% or less&#xD;
             residual thrombus by venogram, as determined by physician, no bleeding, no symptomatic&#xD;
             pulmonary embolism (confirmed by imaging), and no renal compromise (renal compromise&#xD;
             defined as GFR&gt;30). Patients with underlying obstructive lesions can then be included&#xD;
             in the study within the same procedure;&#xD;
&#xD;
          8. Target vessel can accommodate a 9 French Sheath, from insertion site to target&#xD;
             segment;&#xD;
&#xD;
          9. Exchangeable guidewire must cross target lesion(s) with successful predilation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with DVT in the target limb of which the onset of symptoms is between 15 days&#xD;
             and 6 months prior to planned treatment or patient has an acute DVT anywhere else than&#xD;
             in the target vessel;&#xD;
&#xD;
          2. Patient has peripheral arterial disease causing symptoms in target limb;&#xD;
&#xD;
          3. Patient is pregnant, female patients of child-bearing potential must have a negative&#xD;
             pregnancy test done within 7 days prior to the index procedure;&#xD;
&#xD;
          4. Patient has a known or suspected systemic infection at the time of the index&#xD;
             procedure;&#xD;
&#xD;
          5. Patient has a planned percutaneous or surgical intervention within 30 days prior or 30&#xD;
             days following index procedure, or a contralateral iliofemoral lesion requiring&#xD;
             planned treatment within 12 months;&#xD;
&#xD;
          6. Patient requires femoral endovenectomy and patch venoplasty, greater saphenous vein&#xD;
             ablation, and/or small saphenous vein stripping during the index procedure;&#xD;
&#xD;
          7. Patient has an active vasculitic inflammatory disorder (e.g. Behcet disease)&#xD;
             predisposing the patient to thrombosis and requiring systemic corticosteroid therapy;&#xD;
&#xD;
          8. Patient has impaired renal function (GFR &lt; 30) or is on dialysis;&#xD;
&#xD;
          9. Patient has a platelet count &lt; 50,000 cells/mm3 or &gt; 1,000,000 cells/mm3 and/or a&#xD;
             White Blood Cell count &lt; 3,000 cells/mm3 or &gt; 12,500 cells/mm3;&#xD;
&#xD;
         10. Patient has a history of bleeding diathesis or either a history or presence of heparin&#xD;
             induced thrombocytopenia antibodies;&#xD;
&#xD;
         11. Patient has a known hypersensitivity or contraindication to antiplatelets or&#xD;
             anticoagulation, nitinol, or a contrast sensitivity that cannot be adequately&#xD;
             pre-medicated;&#xD;
&#xD;
         12. Patient has presence of other severe co-morbid conditions, which in the investigator's&#xD;
             opinion may interfere with the patient's compliance with study visits and procedures,&#xD;
             or may confound interpretation of study data (e.g. congestive heart failure Class III&#xD;
             and IV, non-ambulatory patients, severe hepatic dysfunction, life expectancy &lt; 1&#xD;
             year);&#xD;
&#xD;
         13. Patient belongs to a vulnerable population per investigator's judgment or patient has&#xD;
             any kind of disorder that compromises his/her ability to give written informed consent&#xD;
             and/or to comply with study procedures. Patient must be able to consent for&#xD;
             themselves;&#xD;
&#xD;
         14. Patient is currently participating in another investigational drug or device study or&#xD;
             observational competitive study.&#xD;
&#xD;
         15. Patient has a vena cava obstruction or lesion extending into the inferior vena cava&#xD;
             (IVC), or the presence of bilateral iliofemoral venous lesions requiring planned&#xD;
             treatment within 12 months;&#xD;
&#xD;
         16. Patient has significant venous bleeding, arterial dissection or other injury requiring&#xD;
             additional percutaneous or surgical intervention prior to enrollment;&#xD;
&#xD;
         17. Patient has a previously placed stent in the ipsilateral venous vasculature;&#xD;
&#xD;
         18. Patient has disease that precludes safe advancement of the venous stent to the target&#xD;
             lesion(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erin Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolinas Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vascular Experts</name>
      <address>
        <city>Darien</city>
        <state>Connecticut</state>
        <zip>06820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Atlanta Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Health System</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Heart and Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Center of Texas</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Vascular Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Washington Vascular, PLLC</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Marseille - Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>D-52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Arnsberg, Karolinen Hospital</name>
      <address>
        <city>Arnsberg</city>
        <zip>D-59759</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galway University Hospitals - University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <zip>H91 YR71</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hesperia Hospital</name>
      <address>
        <city>Modena</city>
        <zip>41125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust - University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas' NHS Foundation Trust - St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 28, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <results_first_submitted>January 4, 2021</results_first_submitted>
  <results_first_submitted_qc>February 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 8, 2021</results_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03038438/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03038438/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were screened for enrollment based on the study Inclusion/Exclusion criteria between December 2017 and November 2018. Included subjects went on to have one or more Abre stents implanted. The first subject was included on December 19, 2017 and the last subject was included on November 29, 2018.</recruitment_details>
      <pre_assignment_details>Of the 260 enrolled subjects, 200 met inclusion criteria and were implanted with the Abre stent(s).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABRE</title>
          <description>Subjects implanted with one or more Abre stents.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>30-Day Follow-Up</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6-Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12-Month Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Incarcerated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABRE</title>
          <description>Subjects included and implanted with one or more Abre stents</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Primary Patency</title>
        <description>Freedom from occlusion of the stented segment; freedom from restenosis &gt;=50%; and Freedom from clinically-driven target lesion revascularization</description>
        <time_frame>12 months</time_frame>
        <population>Subjects evaluable for the primary effectiveness endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Primary Patency</title>
          <description>Freedom from occlusion of the stented segment; freedom from restenosis &gt;=50%; and Freedom from clinically-driven target lesion revascularization</description>
          <population>Subjects evaluable for the primary effectiveness endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The primary effectiveness endpoint, primary patency at 12 months, was tested against a PG of 75%. The null and alternative hypotheses tested appear below:&#xD;
H0: π ≤ PG vs. HA: π &gt; PG where π is the primary patency rate at 12 months in the study population and PG is the performance goal of 75%. The primary effectiveness objective will be met if the lower limit of the 97.5% one-sided confidence interval is above 75%.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Single arm study with a hypothesis test comparing to performance goal</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
            <param_type>proportion</param_type>
            <param_value>88.0</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>82.5</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Composite Major Adverse Events</title>
        <description>The components of the Major Adverse Events include:&#xD;
All-cause death occurring post-procedure, clinically-significant pulmonary embolism, major bleeding complication, stent thrombosis, and stent migration</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite Major Adverse Events</title>
          <description>The components of the Major Adverse Events include:&#xD;
All-cause death occurring post-procedure, clinically-significant pulmonary embolism, major bleeding complication, stent thrombosis, and stent migration</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The primary safety endpoint, major adverse events at 30 days post-procedure, was tested against a performance goal of 12.5%. The null and alternative hypotheses tested appear below:&#xD;
H0: P ≥ PG vs. HA: P &lt; PG where P is the primary safety endpoint at 30 days in the study population and PG is the performance goal.&#xD;
The primary safety objective will be met if the upper limit of the 97.5% one-sided confidence interval is below 12.5%.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Single-arm study with a hypothesis test comparing to performance goal</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
            <param_type>proportion</param_type>
            <param_value>2.0</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success</title>
        <description>Successful delivery and deployment of the stent and removal of the delivery system during the index procedure. Stent based outcome measure.</description>
        <time_frame>Index Procedure</time_frame>
        <population>302 Abre stents were implanted in 200 included subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success</title>
          <description>Successful delivery and deployment of the stent and removal of the delivery system during the index procedure. Stent based outcome measure.</description>
          <population>302 Abre stents were implanted in 200 included subjects.</population>
          <units>Implanted Stents</units>
          <param>Count of Units</param>
          <units_analyzed>Implanted Stents</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implanted Stents</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lesion Success Obtained at Index Procedure</title>
        <description>Venographic evidence of &lt;50% residual stenosis of the stented segment of the target lesion after post-dilation.</description>
        <time_frame>Index Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Lesion Success Obtained at Index Procedure</title>
          <description>Venographic evidence of &lt;50% residual stenosis of the stented segment of the target lesion after post-dilation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Index Procedure Success</title>
        <description>Lesion success without procedure-related MAEs prior to hospital discharge</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Index Procedure Success</title>
          <description>Lesion success without procedure-related MAEs prior to hospital discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Primary Patency at 24 Months</title>
        <description>Freedom from occlusion of the stented segment; freedom from restenosis &gt;=50%; and Freedom from clinically-driven target lesion revascularization</description>
        <time_frame>24 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Primary Patency at 36 Months</title>
        <description>Freedom from occlusion of the stented segment; freedom from restenosis &gt;=50%; and Freedom from clinically-driven target lesion revascularization</description>
        <time_frame>36 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Primary Assisted Patency at 12 Months</title>
        <description>Primary assisted patency is defined as uninterrupted patency of the stented segment of the target lesion with a secondary intervention.</description>
        <time_frame>12 months</time_frame>
        <population>Evaluable subjects</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Primary Assisted Patency at 12 Months</title>
          <description>Primary assisted patency is defined as uninterrupted patency of the stented segment of the target lesion with a secondary intervention.</description>
          <population>Evaluable subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Primary Assisted Patency at 24 Months</title>
        <description>Primary assisted patency is defined as uninterrupted patency of the stented segment of the target lesion with a secondary intervention.</description>
        <time_frame>24 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Primary Assisted Patency at 36 Months</title>
        <description>Primary assisted patency is defined as uninterrupted patency of the stented segment of the target lesion with a secondary intervention.</description>
        <time_frame>36 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Secondary Patency at 12 Months</title>
        <description>Secondary patency is defined as patency of the stented segment of the target lesion after subsequent intervention for an occlusion.</description>
        <time_frame>12 months</time_frame>
        <population>Evaluable subjects</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Secondary Patency at 12 Months</title>
          <description>Secondary patency is defined as patency of the stented segment of the target lesion after subsequent intervention for an occlusion.</description>
          <population>Evaluable subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Secondary Patency at 36 Months</title>
        <description>Secondary patency is defined as patency of the stented segment of the target lesion after subsequent intervention for an occlusion.</description>
        <time_frame>36 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Secondary Patency at 24 Months</title>
        <description>Secondary patency is defined as patency of the stented segment of the target lesion after subsequent intervention for an occlusion.</description>
        <time_frame>24 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization Through 30 Days, 6-, 12 Months</title>
        <time_frame>30 days, 6 months, and 12 months</time_frame>
        <population>Included subjects with an event or a minimum number of follow-up days per time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization Through 30 Days, 6-, 12 Months</title>
          <population>Included subjects with an event or a minimum number of follow-up days per time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 Days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization Through 24 Months</title>
        <time_frame>24 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization Through 36 Months</title>
        <time_frame>36 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Events Through 30 Days, 6-, 12 Months</title>
        <time_frame>30 days, 6 months, and 12 months</time_frame>
        <population>Included subjects with an event or a minimum number of follow-up days per time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Events Through 30 Days, 6-, 12 Months</title>
          <population>Included subjects with an event or a minimum number of follow-up days per time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Within 30 Days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Events Through 24 Months</title>
        <time_frame>24 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Events Through 36 Months</title>
        <time_frame>36 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delayed Stent Migration at 12 Months</title>
        <time_frame>12 months</time_frame>
        <population>Included subjects who had scheduled visit-based evaluable imaging and unscheduled imaging up to day 420</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Delayed Stent Migration at 12 Months</title>
          <population>Included subjects who had scheduled visit-based evaluable imaging and unscheduled imaging up to day 420</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delayed Stent Migration at 24 Months</title>
        <time_frame>24 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delayed Stent Migration at 36 Months</title>
        <time_frame>36 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Fracture at 30 Days, 12 Months</title>
        <time_frame>30 days (30 subjects) and 12 months</time_frame>
        <population>X-ray for the 30-day visit was only required on the first 30 subjects; included subjects who had scheduled visit-based evaluable imaging and unscheduled imaging up to day 420.</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Fracture at 30 Days, 12 Months</title>
          <population>X-ray for the 30-day visit was only required on the first 30 subjects; included subjects who had scheduled visit-based evaluable imaging and unscheduled imaging up to day 420.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-Day</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Fracture at 24 Months</title>
        <time_frame>24 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Fracture at 36 Months</title>
        <time_frame>36 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms QOL/Sym Score at 6-, 12 Months</title>
        <description>Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms (VEINES QOL/Sym). Higher scores correlate to better quality of life on a scale of 1-100. Change in VEINES QOL/Sym scores were calculated as the Baseline score minus the Follow-up score (6 or 12 months). A positive change is associated with improved outcome.</description>
        <time_frame>Baseline to 6 and 12 months</time_frame>
        <population>Subjects with available data at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms QOL/Sym Score at 6-, 12 Months</title>
          <description>Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms (VEINES QOL/Sym). Higher scores correlate to better quality of life on a scale of 1-100. Change in VEINES QOL/Sym scores were calculated as the Baseline score minus the Follow-up score (6 or 12 months). A positive change is associated with improved outcome.</description>
          <population>Subjects with available data at time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VEINES QoL change from Baseline to 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEINES QoL change from Baseline to 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEINES Sym change from Baseline to 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEINES Sym change from Baseline to 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms QOL/Sym Score at 24 Months</title>
        <description>Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms (VEINES QOL/Sym). Higher scores correlate to better quality of life on a scale of 1-100. Change in VEINES QOL/Sym scores were calculated as the Baseline score minus the Follow-up score (24 months). A positive change is associated with improved outcome.</description>
        <time_frame>24 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms QOL/Sym Score at 36 Months</title>
        <description>Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms (VEINES QOL/Sym). Higher scores correlate to better quality of life on a scale of 1-100. Change in VEINES QOL/Sym scores were calculated as the Baseline score minus the Follow-up score (36 months). A positive change is associated with improved outcome.</description>
        <time_frame>36 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Villalta Score at 6-, 12 Months Compared to Baseline</title>
        <description>Villalta scores categorize the severity of post-thrombotic syndrome (PTS). Higher score indicates increasing severity of PTS. A score of greater or equal to 5 indicates PTS. PTS severity: total score of 5 to 9, mild PTS; score of 10 to 14, moderate PTS; and score of greater or equal to 15 or venous ulcer present, severe PTS. Change in Villalta scores were calculated as the Baseline score minus the Follow-up score (6 or 12 months). A negative change is associated with improved outcome.</description>
        <time_frame>Baseline to 6 and 12 months</time_frame>
        <population>Subjects with available data at time point</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Villalta Score at 6-, 12 Months Compared to Baseline</title>
          <description>Villalta scores categorize the severity of post-thrombotic syndrome (PTS). Higher score indicates increasing severity of PTS. A score of greater or equal to 5 indicates PTS. PTS severity: total score of 5 to 9, mild PTS; score of 10 to 14, moderate PTS; and score of greater or equal to 15 or venous ulcer present, severe PTS. Change in Villalta scores were calculated as the Baseline score minus the Follow-up score (6 or 12 months). A negative change is associated with improved outcome.</description>
          <population>Subjects with available data at time point</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to 6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Villalta Score at 24 Months Compared to Baseline</title>
        <description>Villalta scores categorize the severity of post-thrombotic syndrome (PTS). Higher score indicates increasing severity of PTS. A score of greater or equal to 5 indicates PTS. PTS severity: total score of 5 to 9, mild PTS; score of 10 to 14, moderate PTS; and score of greater or equal to 15 or venous ulcer present, severe PTS. Change in Villalta scores were calculated as the Baseline score minus the Follow-up score (24 months). A negative change is associated with improved outcome.</description>
        <time_frame>24 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Villalta Score at 36 Months Compared to Baseline</title>
        <description>Villalta scores categorize the severity of post-thrombotic syndrome (PTS). Higher score indicates increasing severity of PTS. A score of greater or equal to 5 indicates PTS. PTS severity: total score of 5 to 9, mild PTS; score of 10 to 14, moderate PTS; and score of greater or equal to 15 or venous ulcer present, severe PTS. Change in Villalta scores were calculated as the Baseline score minus the Follow-up score (36 months). A negative change is associated with improved outcome.</description>
        <time_frame>36 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in EuroQol-5 Dimension (EQ-5D) Score at 6-, 12 Months Compared to Baseline</title>
        <description>Higher score indicates a better quality of life. The questionnaire contains five dimensions where scores rank from 1 (best) to 5 (worst) plus a visual analog scale (VAS) (0 = worst health; 100 = best health). A positive change is associated with improved outcome. Change in EQ-5D scores were calculated as the Baseline score minus the Follow-up score (6 or 12 months) for both the index and VAS scores.</description>
        <time_frame>Baseline to 6 and 12 Months</time_frame>
        <population>Subjects with available data at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in EuroQol-5 Dimension (EQ-5D) Score at 6-, 12 Months Compared to Baseline</title>
          <description>Higher score indicates a better quality of life. The questionnaire contains five dimensions where scores rank from 1 (best) to 5 (worst) plus a visual analog scale (VAS) (0 = worst health; 100 = best health). A positive change is associated with improved outcome. Change in EQ-5D scores were calculated as the Baseline score minus the Follow-up score (6 or 12 months) for both the index and VAS scores.</description>
          <population>Subjects with available data at time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EQ-5D Index Score change from Baseline to 6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D Index Score change from Baseline to 12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D VAS change from baseline to 6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ-5D VAS change from baseline to 12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in EuroQol-5 Dimension (EQ-5D) Score at 24 Months Compared to Baseline</title>
        <description>Higher score indicates a better quality of life. The questionnaire contains five dimensions where scores rank from 1 (best) to 5 (worst) plus a visual analog scale (VAS) (0 = worst health; 100 = best health). A positive change is associated with improved outcome. Change in EQ-5D scores were calculated as the Baseline score minus the Follow-up score (24 months) for both the index and VAS scores.</description>
        <time_frame>24 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in EuroQol-5 Dimension (EQ-5D) Score at 36 Months Compared to Baseline</title>
        <description>Higher score indicates a better quality of life. The questionnaire contains five dimensions where scores rank from 1 (best) to 5 (worst) plus a visual analog scale (VAS) (0 = worst health; 100 = best health). A positive change is associated with improved outcome. Change in EQ-5D scores were calculated as the Baseline score minus the Follow-up score (36 months) for both the index and VAS scores.</description>
        <time_frame>36 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Venous Clinical Severity Score (VCSS) at 6-, and 12 Months Compared to Baseline</title>
        <description>VCSS scores range from 0=no disease to 30=severe disease. Change in VCSS score was calculated as the Baseline score minus the Follow-up score (6 or 12 months). A negative change is associated with improved outcome.</description>
        <time_frame>Baseline to 6 and 12 months</time_frame>
        <population>Subjects with available data at time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Venous Clinical Severity Score (VCSS) at 6-, and 12 Months Compared to Baseline</title>
          <description>VCSS scores range from 0=no disease to 30=severe disease. Change in VCSS score was calculated as the Baseline score minus the Follow-up score (6 or 12 months). A negative change is associated with improved outcome.</description>
          <population>Subjects with available data at time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to 6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to 12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Venous Clinical Severity Score (VCSS) at 24 Months Compared to Baseline</title>
        <description>VCSS scores range from 0=no disease to 30=severe disease. Change in VCSS score was calculated as the Baseline score minus the Follow-up score (24 months). A negative change is associated with improved outcome.</description>
        <time_frame>24 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Venous Clinical Severity Score (VCSS) at 36 Months Compared to Baseline</title>
        <description>VCSS scores range from 0=no disease to 30=severe disease. Change in VCSS score was calculated as the Baseline score minus the Follow-up score (36 months). A negative change is associated with improved outcome.</description>
        <time_frame>36 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding Complication at 30 Days, 6-, 12 Months</title>
        <description>A blood loss leading to transfusion of whole blood or red cells provided hemoglobin drop of 3 g/dL (1.86 mmol/L) or more is related to bleeding occurring during the index procedure through 12 months post-index procedure.</description>
        <time_frame>30 days, 6 months, and 12 months</time_frame>
        <population>Subjects with an event or a minimum number of follow-up days per time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding Complication at 30 Days, 6-, 12 Months</title>
          <description>A blood loss leading to transfusion of whole blood or red cells provided hemoglobin drop of 3 g/dL (1.86 mmol/L) or more is related to bleeding occurring during the index procedure through 12 months post-index procedure.</description>
          <population>Subjects with an event or a minimum number of follow-up days per time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 Days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding Complication at 24 Months</title>
        <description>A blood loss leading to transfusion of whole blood or red cells provided hemoglobin drop of 3 g/dL (1.86 mmol/L) or more is related to bleeding occurring during the index procedure through 24 months post-index procedure.</description>
        <time_frame>24 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding Complication at 36 Months</title>
        <description>A blood loss leading to transfusion of whole blood or red cells provided hemoglobin drop of 3 g/dL (1.86 mmol/L) or more is related to bleeding occurring during the index procedure through 36 months post-index procedure.</description>
        <time_frame>36 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Re-hospitalization Through 12 Months</title>
        <description>Number of subjects that were re-hospitalized due to their target lesion within 180 days from the Index Procedure and number of subjects that were re-hospitalized due to their target lesion from 181 to 360 days from the Index Procedure.</description>
        <time_frame>6 and 12 months</time_frame>
        <population>Subjects with an event or a minimum number of follow-up days per time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABRE</title>
            <description>Subjects implanted with one or more Abre stents.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Re-hospitalization Through 12 Months</title>
          <description>Number of subjects that were re-hospitalized due to their target lesion within 180 days from the Index Procedure and number of subjects that were re-hospitalized due to their target lesion from 181 to 360 days from the Index Procedure.</description>
          <population>Subjects with an event or a minimum number of follow-up days per time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-180 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>181-360 Days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Re-hospitalization Through 24 Months</title>
        <time_frame>24 Month</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Re-hospitalization Through 36 Months</title>
        <time_frame>36 Month</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 360 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ABRE</title>
          <description>Subjects implanted with one or more Abre stents.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>ANAL FISSURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>MULTIPLE ORGAN DYSFUNCTION SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SWELLING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>VASCULAR STENT STENOSIS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>VASCULAR STENT THROMBOSIS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INTERVERTEBRAL DISCITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>MENISCUS INJURY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>VASCULAR ACCESS SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL ANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>NERVE COMPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>BRONCHIECTASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>STASIS DERMATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>LYMPHOEDEMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VENOUS DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>VENA CAVA THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>VENOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steve Ratchford, Clinical Study Manager</name_or_title>
      <organization>Medtronic</organization>
      <phone>847-710-5440</phone>
      <email>steve.m.ratchford@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

